Skip to main content

Table 6 Risk of ovarian cancer death and CA-125 serum concentration changes 3 and 6 months after therapy in subgroups of patients. NACT-Neoadjuvant chemotherapy

From: Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer

Subgroups of patients Risk of ovarian cancer death - HR (p)
CA-125 changes 3 months
after therapy [U/ml]
CA-125 changes 6 months
after therapy [U/ml]
< 0 0–5 > 5 < 0 0–5 > 5
FIGO 1&2 (n = 52) 1.00 2.76 (p = 0.2065) 5.65 (p = 0.1636) 1.00 1.76 (p = 0.4893) 3.58 (p = 0.2080)
FIGO 3&4 (n = 116) 1.00 1.45 (p = 0.3157) 3.9 (p = 0.0121) 1.00 0.80 (p = 0.5824) 3.11 (p = 0.0037)
Grade 2&3 (n = 152) 1.00 1.90 (p = 0.0617) 3.91 (p = 0.006) 1.00 0.94 (p = 0.8647) 3.24 (p = 0.0015)
Serous (n = 124) 1.00 1.59 (p = 0.191) 4.4 (p = 0.0055) 1.00 0.91 (p = 0.8035) 2.79 (p = 0.0092)
NACT
(n = 26)
1.00 5.14 (p = 0.1322) 7951 (p = 0.9994) 1.00 1.07 (p = 0.9291) 2.14 (p = 0.3347)
Bevacizumab (n = 32) 1.00 3.88 (p = 0.0915) 1.00 0.81 (p = 0.7677) 42.16 (p = 0.0025)
Optimal cytoreduction (< 1 cm) (n = 145) 1.00 2.21 (p = 0.128) 4.05 (p = 0.0958) 1.00 1.09 (p = 0.8648) 3.15 (p = 0.0405)